"At UCSF Health, we're taking every precaution to keep you safe and healthy during the COVID-19 pandemic. For our outpatients, we offer video visits and virtual care for hundreds of conditions as well as for primary care, mental health services, medication monitoring and more. In our hospitals, we test every patient admitted and before most procedures. Our staff wears face masks and practices rigorous hand hygiene, as well as many other methods of infection prevention. Before entering your room, they'll make sure you're masked and (in UCSF Benioff Children's Hospitals) that your child age 2+ is masked. If you're planning to visit someone in the hospital, be sure to check our COVID-19 visitor restrictions before going."

During the past decade, University of California - San Francisco, Department of Ophthalmology conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 6 clinical trials were completed, i.e. on average, 54.5% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 6 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of California - San Francisco, Department of Ophthalmology" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "Jaeb Center for Health Research" with 3 trials sponsored, "AbbVie" with 1 trials sponsored, "Applied Genetic Technologies Corp" with 1 trials sponsored and "Genentech, Inc." with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of California - San Francisco, Department of Ophthalmology" #1 collaborator was "National Eye Institute (NEI)" with 4 trials as a collaborator, "Pediatric Eye Disease Investigator Group" with 3 trials as a collaborator, "Centro Medico ABC" with 1 trials as a collaborator, "Duke University" with 1 trials as a collaborator and "Emory University" with 1 trials as a collaborator. Other collaborators include 24 different institutions and companies that were collaborators in the rest 34 trials.

According to Clinical.Site data, the most researched conditions in "University of California - San Francisco, Department of Ophthalmology" are "Neovascular Age-Related Macular Degeneration" (2 trials), "Retinopathy of Prematurity" (2 trials), "Advanced Retinitis Pigmentosa" (1 trials), "Geographic Atrophy" (1 trials) and "Intermittent Exotropia" (1 trials). Many other conditions were trialed in "University of California - San Francisco, Department of Ophthalmology" in a lesser frequency.

Most popular intervention types in "University of California - San Francisco, Department of Ophthalmology" are "Drug" (8 trials), "Biological" (1 trials), "Device" (1 trials), "Diagnostic Test" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Bevacizumab" (2 trials), "Intravitreal Injections of 10 mg/mL Ranibizumab" (1 trials), "Lampalizumab" (1 trials), "Laser" (1 trials) and "N-acetylcysteine" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of California - San Francisco, Department of Ophthalmology" are 10 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "University of California - San Francisco, Department of Ophthalmology". 1 are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in University of California - San Francisco, Department of Ophthalmology, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in University of California - San Francisco, Department of Ophthalmology, 2 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".